Fusobacterium and Escherichia: Models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 5, 2015, Pages 651-657

  Leung, Andrea ^a,b   Tsoi, Ho ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

biomarker; colorectal cancer; escherichia; fusobacterium; inflammation

Indexed keywords

CHENODEOXYCHOLIC ACID; DEOXYCHOLIC ACID; DNA; ESCHERICHIA COLI PROTEIN; INTERLEUKIN 8; LITHOCHOLIC ACID; RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

CANCER RISK; CANCER SCREENING; CLOSTRIDIA; COLON CARCINOGENESIS; COLON FLORA; COLORECTAL CANCER; DNA METHYLATION; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM VARIUM; HUMAN; MICROBIOME; MUTATIONAL ANALYSIS; NONHUMAN; REVIEW; TUMOR PROMOTION; BIOLOGICAL MODEL; CLOSTRIDIUM; COLON; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; PROCEDURES; RECTUM;

BIOMARKERS; CLOSTRIDIUM; COLON; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; HUMANS; MICROBIOTA; MODELS, BIOLOGICAL; RECTUM;

EID: 84928528828     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1001745     Document Type: Review

References (47)

1. Dove WF, Clipson L, Gould KA, et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 1997; 57(5): 812-14
2. Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 2013; 66(2): 462-70
3. Zhu Q, Jin Z, Wu W, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One 2014; 9(6): e90849
4. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22(2): 292-8
5. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22(2): 299-306
6. Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998; 115(2): 281-6
7. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004; 127(1): 80-93
8. Triantafillidis JK Nasioulas G Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009 29 7 2727-37
9. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002; 97(4): 939-46
10. Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002; 17(8): 849-53
11. Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14(2 207-15
12. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246(1): 379-400
13. Lozyns'ka MR, Plavski A, Lozyns'kyi Iu S. [Clinical and genetic features of APC- and MYH-mutation-negative patients with multiple polyposis of large bowel that tested by conventional methods]. Tsitol Genet 2014; 48(1): 18-24
14. Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14(2): 195-206
15. Okayasu I. Development of ulcerative colitis and its associated colorectal neoplasia as a model of the organ-specific chronic inflammation-carcinoma sequence. Pathol Int 2012; 62(6): 368-80
16. Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 2014; 74(5): 1311-18
17. Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 2014; 20(4): 859-67
18. Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13(10): 1277-83
19. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338(6103): 120-3
20. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15(1): 59-67
21. Cougnoux A, Dalmasso G, Martinez R, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 2014; 63(12): 1932
22. Nesic D, Hsu Y, Stebbins CE. Assembly and function of a bacterial genotoxin. Nature 2004; 429(6990): 429-33
23. Tyrer PC, Frizelle FA, Keenan JI. Escherichia coli-derived outer membrane vesicles are genotoxic to human enterocyte-like cells. Infect Agent Cancer 2014; 9(1): 2
24. Khan AA. In silico prediction of Escherichia coli proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. J Comput Biol 2014; 21(6): 466-75
25. Martin P, Marcq I, Magistro G, et al. Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli. PLoS Pathog 2013; 9(7): e1003437
26. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47(2): 241-59
27. Reddy BS Narasawa T Weisburger JH Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats J Natl Cancer Inst 1976 56 2 441-2
28. Zhu Y, Hua P, Rafiq S, et al. Ca2+- and PKC-dependent stimulation of PGE2 synthesis by deoxycholic acid in human colonic fibroblasts. Am J Physiol Gastrointest Liver Physiol 2002; 283(3): G503-10
29. Gupta S, Natarajan R, Payne SG, et al. Deoxycholic acid activates the c-Jun Nterminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J Biol Chem 2004; 279(7): 5821-8
30. Rao YP, Studer EJ, Stravitz RT, et al. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 2002; 35(2): 307-14
31. Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell 2004; 15(5): 2156-63
32. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3(4): 243-52
33. Prevention CDC. Colorectal cancer tests save lives: office of the associate director for communications (OADC). 2013. Available from: www.cdc.gov/vitalsigns/colorectalcancerscreening/ [cited 2014]
34. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142(2): 81-5
35. Feinman M, Haut ER. Lower gastrointestinal bleeding. Surg Clin North Am 2014; 94(1): 55-63
36. Yeasmin F, Ali MA, Rahman MA, et al. A comparative study of chemical and immunological method of fecal occult blood test in the diagnosis of occult lower gastrointestinal bleeding. Bangladesh Med Res Counc Bull 2013; 39(2): 52-6
37. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370(14): 1287-97
38. Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012; 61(5): 739-45
39. Wu CW, Ng SC, Dong Y, et al. Identification of microRNA-135b in stool as a potential noninvasivebiomarker for colorectal cancer and adenoma. Clin Cancer Res 2014; 20(11): 2994-3002
40. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127(1): 118-26
41. Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 2012; 7(9): e44398
42. Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol 2014. [Epub ahead of print]
43. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6(1): e16393
44. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011; 9(4): 279-90
45. Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014; 33(8): 1381-90
46. Warren RL, Freeman DJ, Pleasance S, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome 2013; 1(1): 16
47. Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing 2013; 10(1): 31